MELODY

Nirsevimab for Prevention of RSV in Healthy Infants

Paziente / Popolazione Intervento / Esposizione Confronto Esito

In 1,490 healthy late-preterm and term infants, a single intramuscular dose of nirsevimab reduced medically attended RSV-associated lower-respiratory-tract infection compared with placebo.

1490

Disegno

Double-blind RCT

Esito

Medically attended RSV-LRTI

Rilevanza

Risultato1.2 % vs 5.0 %; efficacy 74.5 %.

Hammitt LL, et al. N Engl J Med. 2022;386(9):837-846. 10.1056/NEJMoa2110275

Discussione e critica

Established universal infant RSV monoclonal prophylaxis — now standard in many countries during the RSV season.